Drug Pricing Investigation
Loading...
Serial Number
Levin Center Identifier
OR.117.31
Document Date
12/10/2021
Report Length
269 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Report Type
Found Using Methodology
Committee(s)
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
Press Releases and Contextual Information
Related Hearings
House Committee on Oversight and Reform, hearing on "Examining the Actions of Drug Companies in Raising Prescription Drug Prices," 116th Cong., (2019, January 29)
House Committee on Oversight and Reform hearing, "The Patient Perspective: The Devastating Impacts of Skyrocketing Drug Prices on American Families," 116th Cong., H.Hrg. 116-55, (2019, July 26)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Parts I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Parts II)," 116th Cong. H.Hrg. 116-123, (2020, October 1)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., (2021, May 18)
House Committee on Oversight and Reform hearing, "The Patient Perspective: The Devastating Impacts of Skyrocketing Drug Prices on American Families," 116th Cong., H.Hrg. 116-55, (2019, July 26)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Parts I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Parts II)," 116th Cong. H.Hrg. 116-123, (2020, October 1)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., (2021, May 18)